{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Measurable+Residual+Disease",
    "query": {
      "condition": "Measurable Residual Disease"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 185,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Measurable+Residual+Disease&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T03:50:20.314Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03901963",
      "title": "A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Daratumumab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 200,
      "start_date": "2019-04-26",
      "completion_date": "2026-05-04",
      "has_results": true,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-07-24T03:50:20.314Z",
      "location_count": 70,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Goodyear, Arizona + 57 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03901963"
    },
    {
      "nct_id": "NCT05307939",
      "title": "A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HPV",
        "Oropharynx Cancer",
        "HPV-Related Carcinoma",
        "HPV-Related Malignancy",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "HPV ctDNA Assay",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "MRI Studies",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "EORTC QLQ H&N 35 and C30",
          "type": "BEHAVIORAL"
        },
        {
          "name": "MDADI-HN",
          "type": "BEHAVIORAL"
        },
        {
          "name": "COST-FACIT",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy (Arm A)",
          "type": "RADIATION"
        },
        {
          "name": "Chemoradiation (Arm B)",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "BEHAVIORAL",
        "RADIATION",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2022-03-24",
      "completion_date": "2027-03-24",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-07-24T03:50:20.314Z",
      "location_count": 8,
      "location_summary": "Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05307939"
    },
    {
      "nct_id": "NCT07566364",
      "title": "Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Mosunetuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-10-01",
      "completion_date": "2030-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-07-24T03:50:20.314Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07566364"
    },
    {
      "nct_id": "NCT06333678",
      "title": "A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Sotorasib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2024-03-20",
      "completion_date": "2026-01-27",
      "has_results": false,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-07-24T03:50:20.314Z",
      "location_count": 10,
      "location_summary": "Miami, Florida • Ann Arbor, Michigan • Basking Ridge, New Jersey + 7 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06333678"
    },
    {
      "nct_id": "NCT03863184",
      "title": "Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Acalabrutinib",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2019-10-11",
      "completion_date": "2028-05-30",
      "has_results": true,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-07-24T03:50:20.314Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03863184"
    },
    {
      "nct_id": "NCT02477878",
      "title": "Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Lymphoma",
        "Multiple Myeloma",
        "Hematologic Neoplasms"
      ],
      "interventions": [
        {
          "name": "BPX-501",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rimiducid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bellicum Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2016-07",
      "completion_date": "2033-01",
      "has_results": false,
      "last_update_posted_date": "2022-07-12",
      "last_synced_at": "2026-07-24T03:50:20.314Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Westwood, Kansas • Buffalo, New York + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02477878"
    },
    {
      "nct_id": "NCT04876248",
      "title": "Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Belantamab Mafodotin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2024-08-19",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-07-24T03:50:20.314Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04876248"
    },
    {
      "nct_id": "NCT04853017",
      "title": "A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Minimal Residual Disease",
        "KRAS G12D",
        "KRAS G12R",
        "NRAS G12D",
        "NRAS G12R",
        "Pancreatic Ductal Adenocarcinoma",
        "Colorectal Cancer",
        "Non-small Cell Lung Cancer",
        "Ovarian Cancer",
        "Cholangiocarcinoma",
        "Bile Duct Cancer",
        "Gallbladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "ELI-002 2P",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elicio Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-10-04",
      "completion_date": "2024-09-24",
      "has_results": true,
      "last_update_posted_date": "2025-09-05",
      "last_synced_at": "2026-07-24T03:50:20.314Z",
      "location_count": 10,
      "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04853017"
    },
    {
      "nct_id": "NCT04634435",
      "title": "Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Biohaven Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 7,
      "start_date": "2021-10-21",
      "completion_date": "2025-01-10",
      "has_results": false,
      "last_update_posted_date": "2025-01-20",
      "last_synced_at": "2026-07-24T03:50:20.314Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04634435"
    },
    {
      "nct_id": "NCT01499394",
      "title": "Caris Biorepository Research Protocol",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer",
        "Early Detection of Cancer",
        "Minimal Residual Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Caris Science, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100000,
      "start_date": "2010-11",
      "completion_date": "2035-11",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-07-24T03:50:20.314Z",
      "location_count": 38,
      "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 32 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01499394"
    }
  ]
}